The Future of Obesity Pharmacotherapy: From Single Agonists to Combination Approaches

A Decade of Transformation

The landscape of obesity pharmacotherapy has undergone more change in the past five years than in the preceding five decades. For most of modern medicine, the available drugs for obesity were marginally effective, poorly tolerated, or burdened by safety concerns that led to market withdrawals. The arrival of potent incretin-based therapies has fundamentally altered what is pharmacologically achievable — and raised expectations for what comes next.

The Progression of Receptor Targeting

The trajectory is clear in retrospect. Liraglutide, a GLP-1 receptor agonist approved for obesity in 2014, produced approximately 8% mean weight loss. Semaglutide 2.4 mg, a more potent and longer-acting GLP-1 agonist, pushed this to roughly 15%. Tirzepatide, a dual GIP/GLP-1 agonist, reached approximately 22%. And retatrutide, adding glucagon receptor agonism to create a triple agonist, has shown up to 24% in Phase 2 data at a shorter treatment duration.

Each step has added a receptor target and incrementally increased efficacy. But this progression also raises a fundamental question: is more receptor activation always better, or are we approaching diminishing returns?

The Glucagon Component: What It Adds

Retatrutide’s distinguishing feature is its glucagon receptor agonism. While GLP-1 and GIP primarily reduce energy intake through appetite suppression and metabolic signaling, glucagon receptor activation is thought to increase energy expenditure. Preclinical data from Coskun et al. showed that the triple combination produced greater weight loss and improvements in hepatic steatosis than dual agonism alone.

If this translates robustly to humans — as Phase 2 data suggest — it represents a mechanistically important advance. Obesity treatment has historically focused almost entirely on reducing caloric intake. A therapy that meaningfully increases energy expenditure addresses the other side of the energy balance equation, potentially producing more durable weight loss and better metabolic outcomes.

Combination Strategies: CagriSema and Beyond

An alternative approach to multi-receptor agonism is combination therapy using separate agents. CagriSema, developed by Novo Nordisk, combines semaglutide (a GLP-1 agonist) with cagrilintide (a long-acting amylin analog). By targeting complementary appetite-regulating pathways, this combination has shown weight loss in the range of 20-25% in clinical trials.

The combinatorial approach offers different advantages: individual dose adjustment of each component, and the ability to add or remove components based on patient response and tolerability. However, it also introduces complexity in manufacturing, administration, and cost.

Other pipeline candidates are exploring additional mechanisms:

• Survodutide (Boehringer Ingelheim): a dual GLP-1/glucagon agonist, testing a different ratio of receptor activation than retatrutide.
• Orforglipron (Eli Lilly): a small-molecule oral GLP-1 agonist, which could dramatically expand access by eliminating the need for injections.
• Bimagrumab and related myostatin/activin inhibitors: aimed at preserving or building lean mass during weight loss, addressing the concern that significant weight reduction includes loss of muscle as well as fat.

The Oral Frontier

One of the most significant developments on the horizon is the maturation of oral incretin therapies. Currently, all potent GLP-1 class drugs require subcutaneous injection, which creates barriers related to needle aversion, cold-chain storage, and drug delivery infrastructure.

Oral semaglutide (Rybelsus) exists but at lower doses with more modest weight loss effects. Higher-dose oral formulations and entirely new oral molecules like orforglipron could make obesity pharmacotherapy as accessible as taking a daily pill. If retatrutide or a similar triple agonist could eventually be delivered orally, the implications for global obesity treatment would be substantial.

Muscle Preservation: The Next Frontier

A growing concern in the field is the composition of weight lost during treatment. Approximately 25-40% of weight lost with GLP-1 class drugs may be lean mass, including muscle. While this ratio is comparable to diet-induced weight loss, the absolute amount of muscle lost at 20-25% total body weight reduction is clinically significant, particularly for older adults at risk of sarcopenia.

This has spurred interest in combination approaches that pair weight loss agents with anabolic therapies targeting muscle. Whether such combinations prove practical and effective will be an important question for the next generation of obesity treatment.

Where Retatrutide Fits

Retatrutide occupies a specific and potentially important position in this evolving landscape: it is the most advanced triple-agonist candidate, with Phase 3 data expected to define its role. If confirmed, its combination of potent weight loss, energy expenditure effects, and hepatic benefits could make it particularly suited for patients with severe obesity and metabolic comorbidities — especially MASLD.

However, it is unlikely to be the final word. The field is moving rapidly, and the next decade will likely bring further innovations in targeting, delivery, and combination strategies. The most important development is not any single molecule, but the broader recognition that obesity is a chronic, treatable disease deserving the same pharmacological rigor applied to hypertension, diabetes, and hyperlipidemia.

A Balanced Perspective

Enthusiasm should be tempered by realism. Long-term safety data for newer agents remain limited. Weight regain after discontinuation is a consistent finding across the class. Cost and access remain major barriers globally. And pharmacotherapy alone cannot address the environmental and systemic factors that drive obesity prevalence.

Still, the trajectory is unmistakable. The era of effective obesity pharmacotherapy has arrived, and retatrutide represents one of its most promising chapters — though certainly not its last.